Ufuk Cakir, Cuneyt Tayman, Dilek Gurlek Gokcebay, Burak Ceran, Turan Derme, Mehmet Orhan Erkan, Seda Sahin

A down syndrome patient diagnosed with transient myeloproliferative disease after presenting with cutaneous findings

Transient myeloproliferative disease (TMD) is among the main hematologic problems seen in neonates with Down syndrome (DS). It is usually self-limiting and results in spontaneous remission within 3 to 6 months. Characteristic signs of TMD are leukocytosis, thrombocytopenia, anemia, hepatosplenomegaly, cutaneous nodules, and increased numbers of circulating blasts. In this article, we present a DS neonate without leukocytosis who was diagnosed as having TMD after a diffuse vesiculopapular eruption on the face, which is a different clinical presentation than other cases in the literature. Our aim is to emphasize the importance of early diagnosis and close multidisciplinary monitoring of these patients.

PDF

___

1. Zipursky A. Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 2003;120:930-8.
2. Pine SR, Guo Q, Yin C, et al. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 2007;110:2128-31.
3. Roberts I, Alford K, Hall G, Juban G, Richmond H. GATA1- mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood 2013;122:3908- 17.
4. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood 2011;118:6752-96.
5. Boos M, Wine Lee L, Freedman JL, et al. Presentation of acute megakaryoblastic leukemia associated with a GATA1 mutation mimicking the eruption of transient myeloproliferative disorder. Pediatr Dermatol. 2015;32:204-7.
6. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood 2006;107:4606-13.
7. Klusmann JH, Creutzig U, Zimmerman M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008;111:2991-8.
8. Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down’s syndrome. Blood 1988;72:15-23.
9. Tugcu AU, Apak BB, Ince-Anuk D, et al. Transient Abnormal Myelopoiesis in a Newborn with Mosaic Down Sydrome. Turk J Pediatr 2019;13:496-8.
10. Narvaez-Rosales V, de-Ocariz MS, Carrasco-Daza D, et al. Neonatal vesiculopustular eruption associated with transient myeloproliferative disorder: report of four cases. Int J Dermatol 2013;52:1202-9.
11. Nijhawan A, Baselga E, Gonzalez-Ensenat MA, et al. Vesiculopustular eruptions in Down syndrome neonates with myeloproliferative disorders. AMA Arch Derm 2001;137:760-3.
12. Alford KA, Reinhardt K, Garnett C, et al. International Myeloid Leukemia-Down Syndrome Study Group. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood 2011;118:2222-8.
13. Roy A, Roberts I, Vyas P. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Semin Fetal Neonatal Med 2012;17:196-201.